About 60% of patients with chronic pain also suffer from a second condition like depression or anxiety.
A University of Tasmania researcher predicts that ketamine therapy will have a “dual beneficial effect” on both pain and mental health.
Other chronic pain experts share this belief. “The domains of pain, anxiety and depression are all connected. If you treat one, another often gets better,” according to researcher Dr. David Borsook.
The hypothesis will be put to the test in an upcoming study of 30 chronic pain patients, which received a $80K grant from the Clifford Craig Foundation.
CAPE TOWN, SA / ACCESSWIRE / March 10, 2022 / WUHAN GENERAL GROUP, INC. (WUHN) (“WGG” or the “Company”), a bioceutical company focused on alternative plant-based cannabinoids and mental health therapeutic research is pleased to share the following update:
M2Bio Sciences is pleased to announce the rollout of its on-site Ketamine and Supercharged Vitamin IV Therapy at the M2Bio Labs in Hout Bay, Cape Town.
Drip therapy has long been used in hospitals and clinics to administer medicine for the main benefit of 100% bioavailability. This means that all the medicine, nutrients, or minerals are absorbed by the body because it’s being fed directly into the bloodstream.
Supercharged Vitamin and CBD IV Drip
The customized intravenous vitamin drips will offer various therapies and vitamin cocktails designed to target very specific health needs. They will support your physical and mental well-being, detox the body, boost the immune system, assist with recovery from strenuous training sessions, nourish and repair hair, skin, and nails, all to get your mind and body to peak performance.
The drips will offer the following benefits to clients:
Instantly increase the body’s antioxidant, mineral, and nutrient count.
Oxygenate the blood, flush out toxins, help with lymph production.
Increase energy, lower body temperature, decrease constipation.
Reduce swelling and help fight off infections.
Improve sleep quality.
Increased metabolism and potential weight loss.
Aids fertility and libido.
Improve concentration and mental clarity.
There will also be the option of CBD (cannabidiol) vitamin drip as part of the product offering. The IV drip method is the fastest and most effective way to get CBD into the patients’ endocannabinoid system and is far more effective than traditional oral, inhaled, transdermal, or sublingual delivery methods.
Ketamine IV Infusions and Assisted Psychotherapy (KAP)
The labs will also feature a Ketamine Infusion Facility and Ketamine Assisted Psychotherapy for treating patients with mental illness, mood disorders, and chronic pain, these include:
Treatment Resistant Depression
Suicidality
Eating Disorders
Bipolar Disorder
Anxiety and Panic Attacks
PTSD
OCD
Postpartum Depression
Alcoholism and Addiction
Neuralgia
Neuropathic pain associated with Diabetes, Demyelination, Cancer, or HIV.
Complex Regional Pain Syndrome (CRPS).
Pain associated with Multiple Sclerosis or Parkinson’s disease.
Migraine headaches and Fibromyalgia.
Patients will be treated in sessions typically lasting 2-3 hours, this process includes the ketamine administration by fully qualified members of the medical team in a comfortable environment. The medical staff will consist of doctors, nurses, psychologists, and psychiatrists. Patients will be fully guided through the entire process.
“We are very excited about the addition of the IV Vitamin and Ketamine divisions. This will add great depth and value to our current offerings at M2Bio Labs. Our clients and patients will have the opportunity to experience various mental and physical wellness therapies all in one convenient location. We will change many lives for the better at the labs.” said Jeff Robinson, Wuhan General Inc, CEO.
About Ketamine and Ketamine Assisted Psychotherapy
Ketamine is an FDA-approved anesthetic that’s been widely used around the world for more than five decades. It’s also a medication with fast-acting antidepressant properties.
While ketamine isn’t considered a first-line therapy for chronic pain, depression, or any other mental health disorder, it can be used off-label to treat severe cases of depression, anxiety, and PTSD that haven’t responded to conventional medications or therapies.
When ketamine is administered through a slow, constant intravenous (IV) drip, it has calming and therapeutic effects on the regions of your brain that control mood and behavior.
KAP is an integrative psychotherapeutic modality.
By using this therapy during a non-ordinary state of consciousness, the therapist is able to support the patient in their exploration of particular suppressed material with less resistance. The client is encouraged to share as much, or as little as they wish during the administration session. Once the client has fully reconnected with their environment, an integration session is used to explore and make meaning of the material, together with the therapist. There is a strong emphasis on mindfulness, the re-examination of one’s core values, and how to apply value-driven actions into the client’s current life circumstances.
About Wuhan General Group, Inc./ M2Bio Sciences, Inc
Wuhan General Group, Inc. (DBA M2bio Sciences), through its wholly-owned subsidiary MJ MedTech is a nutraceutical biotechnology company focused on alternative plant-based cannabinoids and psilocybin medical research that develops and commercializes a range of CBD and mushrooms-based products under Dr. AnnaRx™, Medspresso™, and Liviana™ brands. In addition, our research and clinical trials with psilocybin are aimed at new therapies that will help patients who suffer from alcohol addiction, mental illness, and cardiovascular diseases. Our mission is to advance botanical-based medicine to the forefront by deploying best-practice science and medicine, clinical research, and emerging technologies. The Company is traded on the Over-the-Counter Bulletin Board of NASDAQ under the trading symbol “WUHN”.
Safe Harbour Statement – In addition to historical information, this press release may contain statements that constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release include the intent, belief, or expectations of the Company and members of its management team with respect to the Company’s future business operations and the assumptions upon which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance, and involve risks and uncertainties and that actual results may differ materially from those contemplated by such forward-looking statements. Factors that could cause these differences include, but are not limited to, failure to complete anticipated sales under negotiations, lack of revenue growth, client discontinuances, failure to realize improvements in performance, efficiency and profitability, and adverse developments with respect to litigation or increased litigation costs, the operation or performance of the Company’s business units or the market price of its common stock. Additional factors that could cause actual results to differ materially from those contemplated within this press release can also be found on the Company’s website. The Company disclaims any responsibility to update any forward-looking statements.
SOURCE: Wuhan General Group, Inc./ M2Bio Sciences, Inc.
The pioneer psychedelic therapy company is partnering with the rapidly growing online mental health platform to create a comprehensive mental health offering for consumers
TORONTO, March 3, 2022 /PRNewswire/ — Field Trip Health Ltd. (NASDAQ: FTRP, TSX: FTRP) (“Field Trip”), a global leader in the development and delivery of psychedelic-assisted psychotherapy, today announced a strategic partnership with Cerebral, the fastest growing online mental health platform. The companies are launching a partnership where Cerebral clinicians can refer qualified clients to Field Trip Health’s ketamine assisted therapy, while Field Trip will connect potential clients seeking general psychiatry and teletherapy services to Cerebral. This end-to-end solution will provide personalized treatment solutions for those seeking to improve their mental health.
Field Trip Health currently has clinics operating in eight major U.S. cities, making it the largest provider of psychedelic-assisted therapies in North America. With this partnership, Field Trip Health patients will have access to services beyond psychedelic treatments and can now access a holistic offering of mental health treatments through Cerebral.
“Our partnership with Cerebral will lower the barriers of entry into ketamine assisted therapy for many people who have solely been exposed to generalized psychiatry or might have not been presented with an alternative of exploring a healing journey propelled through psychedelics,” said Ronan Levy, Field Trip’s Executive Chairman. “We’re excited to be Cerebral’s preferred platform to refer patients to. Together we will help change the mental health landscape by bringing together teletherapy, telepsychiatry, and psychedelic-assisted therapy and offer more comprehensive benefits to consumers’ mental health.”
Cerebral’s mission is to improve access to long-term, high-quality comprehensive mental health care through affordable plans on their online mental health platform which provides comprehensive care including therapy, counseling, and medication management. Cerebral’s platform allows members to schedule and meet with their care team online and provides medication management and delivery straight to your door.
“The recent shift in the mental health landscape has resulted in a need for modernized, digitized, and personalized solutions. At its core, Cerebral believes that everyone deserves access to individualized, non-judgmental mental health care,” added Dr. David Mou, Cerebral’s Chief Medical Officer. “We’re constantly searching for novel ways to work towards that goal, which is why we chose to partner with Field Trip, a like-minded company with an aligning ethos that brings psychedelic-assisted psychotherapy to the table for our clients,”
About Field Trip Health Ltd.
Field Trip is a global leader in the development and delivery of psychedelic therapies. With our Field Trip Discovery division leading the development of the next generation of psychedelic molecules and conducting advanced research on plant-based psychedelics and our Field Trip Health division building centers for psychedelic therapies opening across North America and Europe along with the digital and technological tools that will enable massive scale, we help people in need with a simple, evidence-based way to heal and heighten engagement with the world.
Follow us on Twitter and Instagram: @fieldtriphealth
About Cerebral
Cerebral’s mission is simple and straightforward: To improve access to long-term, high-quality mental health care to all. Unlike traditional mental health care, Cerebral is accessible, convenient, affordable, and free of stigma. With several full-service monthly subscription plans to choose from, members receive online access to prescribing providers, behavioral counselors, and talk therapists—all from the comfort of home or anywhere else with an internet connection. Visits are done via video chat, and members can message their care team directly. Members can even receive medications delivered straight to their door (if prescribed). Cerebral was founded and launched in January 2020 by CEO Kyle Robertson. For more information, visit www.cerebral.com
To receive company updates about Field Trip and to be added to the email distribution list please sign up here.
This release includes forward-looking information (within the meaning of Canadian securities laws and within the meaning of the United States Private Securities Litigation Reform Act of 1995) regarding Field Trip and its business. Often but not always, forward-looking information can be identified by the use of words such as “expect”, “intends”, “anticipated”, “believes” or variations (including negative variations) of such words and phrases, or state that certain actions, events or results “may”, “could”, “would” or “will” be taken, occur or be achieved. Such statements are based on the current expectations and views of future events of the management of Field Trip, and are based on assumptions and subject to risks and uncertainties. Although the management of Field Trip believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect. The forward-looking events and circumstances discussed in this release may not occur and could differ materially as a result of known and unknown risk factors and uncertainties affecting the companies, including commencement, uptake and success of the referral relationship between Cerebral and Field Trip, factors affecting the medical clinic industry, market conditions, economic factors, management’s ability to manage and to operate the business and the equity markets generally. Although Field Trip has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. Accordingly, readers should not place undue reliance on any forward-looking statements or information. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and Field Trip does not undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise. For a more detailed discussion of risks and other factors, see Field Trip’s amended Annual Information Form dated July 16, 2021 under the heading “Risk Factors”, or otherwise disclosed in the public filings made with applicable securities regulatory authorities and available under Field Trip’s SEDAR and EDGAR profiles.
This press release does not constitute an offer to sell or the solicitation of an offer to buy securities.
Neither the Toronto Stock Exchange nor its Regulation Services Provider, have approved the contents of this release or accept responsibility for the adequacy or accuracy of this release.
Entheon Biomedical (ENBI) initiated a ketamine study on treatment resistant depression in partnership with Wavepaths. It will monitor brain activity with EEG while assessing the impact of Wavepaths’ personalized music technology.
nnovative treatment is a candidate to become regular service offering for healthcare workers
TORONTO, ON / February 16, 2022 / Novamind Inc. (CSE: NM | OTCQB: NVMDF | FSE: HN2) (“Novamind” or the “Company”), a leading mental health company specialized in psychedelic medicine, is pleased to update shareholders on a clinical pilot investigating the efficacy of group ketamine-assisted psychotherapy for frontline healthcare workers (“Frontline KAP”). With the final cohort of participants expected to begin treatment in March 2022, data analysis is currently underway and will be published following completion of the clinical pilot.
Frontline KAP represents a unique opportunity for Novamind to scale an innovative research pilot into a novel treatment program and make it accessible at all Novamind clinics. The pilot launched in July 2021, in partnership with Colorado-based Wholeness Center, to address pandemic-related stress and trauma in frontline healthcare workers. Novamind’s Chief Medical Officer, Dr. Reid Robison, and Wholeness Center’s Dr. Scott Shannon designed a six-session KAP protocol delivered in a group setting. A cohort of 40 participants are enrolled in the pilot across research sites in Utah and Colorado.
“Frontline KAP is an example of real-time, evidence-based innovation that leverages Novamind’s clinical and research expertise to bring new treatments to patient groups in need” said Yaron Conforti, CEO and Director, Novamind. “The risk of burnout in healthcare professions is strikingly high, particularly during the pandemic. We designed a protocol addressing an unmet need for healthcare workers, we’re completing the clinical pilot at our research sites, and we anticipate that Frontline KAP will be an accessible treatment available at all Novamind clinics.”
Ketamine has demonstrated efficacy for rapid relief from symptoms of depression, while the group setting provides a platform for processing trauma with peers, more effectively building community and reducing feelings of isolation compared to individual treatment. Frontline KAP involves a ratio of two therapists to four patients per cohort, greatly reducing the total number of therapist hours when compared to traditional one-on-one treatment, which increases the treatment’s affordability and enables Novamind to serve a larger patient population.
“Frontline KAP has been incredibly rewarding and meaningful for everyone involved as we’ve witnessed first-hand the healing potential of ketamine-assisted psychotherapy in a group setting that uses the power of social connection,” said Dr. Robison.
He continued, “Interim data from the pilot shows depression and anxiety scores trending down, and resilience scores going up. Many participants report having breakthroughs when assisted by the ketamine treatments, and that’s further enhanced by processing the experiences in a group setting with peers. We’re looking forward to completing the pilot and exploring the opportunity to scale access to this innovative treatment at Novamind clinics.”
To learn more about the Frontline KAP clinical pilot, please visit this link.
PharmaTher (PHRM) was granted a US patent for its formulation of ketamine and betaine anhydrous, a chemical that occurs naturally in the human body and may increase ketamine’s antidepressant effect. The formulation is already patented in Japan and Taiwan, and the company expects to receive patents in Europe, Canada, Israel and China in the near future.
Despite having a supportive family and a healthy lifestyle, Sarah had crippling self doubt and suicidal ideation. It wasn’t until she tried ketamine therapy that she realized why she felt these emotions.
The experience revealed that she never healed the scars of feeling unloved during her parents’ divorce. Her dream-like visions on ketamine showed her that separation is a natural part of life, and that she doesn’t need to be perfect to deserve love.
Sarah finally believes “I’m worth being here,’ she says.
The Treatment was Successfully Performed in Ontario as Part of the Company’s Previously Announced Collaboration with Victoria Wellness and iHealthOX
Vancouver, British Columbia, February 15, 2022 / Globe Newswire / – Wellbeing Digital Sciences Inc. (“Wellbeing” or the “Company”) (NEO: MEDI) (OTC: KONEF) (Frankfurt: MY0), an evidence based healthcare company focused on innovative clinical solutions, artificial intelligence-powered digital therapeutics and contract research, is pleased to announce the successful facilitation of its first intravenous (“IV”) ketamine treatment to a patient at the Victoria Wellness Mental Health Residential and Addition Treatment Centre (“VW” or the “Centre”) in Ontario through its collaboration with iHealthOX. VW is one of the first in-patient facilities to offer ketamine-assisted therapy in Canada. Wellbeing management expects the collaboration between VW, iHealthOX and itself to experience an increase in the number of patients treated via IV ketamine infusions in the near future.
The Centre, located at 5316 Rice Lake Scenic Drive in Gores Landing, Ontario, is a residential rehabilitation facility and mental health clinic focused on treating anxiety, depression, and post-traumatic stress disorder (“PTSD”) by offering personalized therapy treatment programs. The Company and VW have launched a first-class, best practice-based, six-week inpatient Ketamine Integrated Therapy Experience (“KITE”) program. The first three weeks of the KITE program are structured to offer clients a unique opportunity to benefit from fast-acting and medically supervised IV ketamine administration. This process is expected to help combat long-standing and prescription-resistant mental health conditions such as depression and PTSD.
The Company’s previous announced arrangement with iHealthOX helped to make this first IV ketamine treatment possible. iHealthOX was created to provide patients with a customized digital tool specifically for mental health. Patients have access to live coaching sessions, options for one-on-one therapy, evidence based educational material, and 24/7 emergency support. The iHealthOX platform will be available to patients in both desktop and mobile versions, thereby extending the Company’s services beyond its clinic locations.
“The success of our first IV ketamine treatment in Canada in collaboration with VW and iHealthOX and Wellbeing is encouraged that ketamine-based treatments for mental health are becoming more commonplace. The Company has always wanted to make a positive and significant impact on mental health and this brings us one step closer,” said Adam Deffett, Interim CEO of Wellbeing. “Achievements like this,
exemplify why Wellbeing continues to work hard to make a difference in the mental health realm,” added Mr. Deffett.
ABOUT WELLBEING DIGITAL SCIENCES
Wellbeing Digital Sciences Inc. (formerly KetamineOne Capital Limited) is an evidence-based healthcare company focused on innovative clinical solutions, artificial intelligence-powered digital therapeutics and contract research. Its mission is supported by a network of North American clinics that provide ketamine assisted therapies and other types of treatment to patients as well as through a contract research organization that offer clinical trials services to clients pursuing drug development. In essence, the company exists to make breakthrough treatments more accessible and to offer patients transformational experiences.
On behalf of:
WELLBEING DIGITAL SCIENCES INC.
“Adam Deffett”
Adam Deffett, Interim CEO
For further information, please contact:
Nick Kuzyk, Investor Relations
Tel: 1-844-746-6351
Email: ir@wellbeingdigital.co
Web: www.wellbeingdigital.co
Twitter: @Wellbeing_IR
Notice Regarding Forward-Looking Information:
This news release contains forward-looking statements including but not limited to statements regarding the Company’s business, assets or investments, as well other statements that are not historical facts. Readers are cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are based will occur. By their nature, forward-looking statements involve numerous assumptions, known and unknown risks and uncertainties, both general and specific, that contribute to the possibility that the predictions, forecasts, projections and other forward
looking statements will not occur, which may cause actual performance and results in future periods to differ materially from any estimates or projections of future performance or results expressed or implied by such forward-looking statements. These assumptions, risks and uncertainties include, among other things, the state of the economy in general and capital markets in particular, investor interest in the business and prospects of the Company.
The forward-looking statements contained in this news release are made as of the date of this news release. Except as required by law, the Company disclaims any intention and assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable securities law. Additionally, the Company undertakes no obligation to comment on the expectations of, or statements made, by third parties in respect of the matters discussed above.
TORONTO, ONTARIO January 31, 2022 – Braxia Scientific Corp. (“Braxia”, or the “Company”), (CSE: BRAX) (OTC: BRAXF) (FWB: 4960), a medical research company with clinics providing innovative ketamine treatments for persons with depression and related disorders, today provided an update on the Company’s leading research role within the psychedelics industry. As the Company continues to focus on developing innovative treatments for depression, including potential ketamine derivatives, Braxia Scientific’s team of researchers also continue to carry out multiple psychedelic-based clinical research trials, adding to the Company’s large and growing proprietary dataset critical to informing future drug development.
To date, Braxia Scientific has compiled comprehensive health data from administering more than 5,200 ketamine treatments at its network of clinics. Additionally, Braxia Scientific’s researchers have published 43 ketamine-related manuscripts in peer-reviewed biomedical journals, and the Canadian Rapid Treatment Centre of Excellence (CRTCE), a wholly owned Braxia subsidiary, has established a growing database with key clinical outcomes for an ongoing clinical trial evaluating psilocybin-assisted therapy.
“We are tremendously proud of our research team, which includes three individuals ranked among the world’s top 20 experts in depression, mood disorders and ketamine research,” said Dr. Roger McIntyre, CEO of Braxia Scientific. “With our unmatched human capital, well-established clinical infrastructure and large proprietary health database we believe Braxia Scientific has a distinct competitive advantage among the leading groups endeavouring to develop new psychedelic treatments.
“With this expertise and data, we are well-positioned to enhance our intellectual property, including our work to identify and develop new chemical entities, while providing patients with access to new pathways to treat their mental health disorders.”
Building on management’s extensive clinical expertise, the Company has expanded the necessary infrastructure to provide innovative interventions that include ketamine, psilocybin and other potential future psychedelics that become available.
The Company also continues to exhibit itself as a leader in the psychedelics industry, establishing treatment protocols and best practice guidelines, including for innovative potential therapies, such as psilocybin. The Company’s leadership is illustrated by the publication by the American Journal of Psychiatry of the International Expert Opinion and Implementation Guidance, led by Braxia Scientific’s leaders, which outlines Ketamine and Esketamine treatment parameters and sets the standard for the clinical implementation of rapid-acting treatments in persons with treatment-resistant depression.
About Braxia Scientific Corp.
Braxia Scientific is a medical research company with clinics that provide innovative ketamine treatments for persons with depression and related disorders. Through its medical solutions, Braxia aims to reduce the illness burden of brain-based mental disorders such as major depressive disorder among others. Braxia is primarily focused on (i) owning and operating multidisciplinary clinics, providing treatment for mental health disorders, and (ii) research activities related to discovering and commercializing novel drugs and delivery methods. Braxia seeks to develop ketamine and derivatives and other psychedelic products from its IP development platform. Through its wholly
owned subsidiary, the Canadian Rapid Treatment Center of Excellence Inc., Braxia currently operates multidisciplinary community-based clinics offering rapid-acting treatments for depression located in Mississauga, Toronto, Ottawa, and Montreal.
ON BEHALF OF THE BOARD
“Dr. Roger S. McIntyre” Dr. Roger S. McIntyre
Chairman & CEO
– 30 –
FOR FURTHER INFORMATION PLEASE CONTACT:
Braxia Scientific Corp.
Tel: 416-762-2138
Email: info@braxiascientific.com
Website: www.braxiascientific.com
The CSE has not reviewed and does not accept responsibility for the accuracy or adequacy of this release.
Forward-looking Information Cautionary Statement This news release contains forward-looking statements within the meaning of applicable securities laws. All statements that are not historical facts, future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations, or beliefs of future performance are “forward-looking statements.”
Forward-looking statements include statements about the intended promise of ketamine-based treatments for depression and the potential for ketamine to treat other emerging psychiatric disorders, such as Bipolar Depression. Such forward- looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, events, or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such risks and uncertainties include, among others, the failure of ketamine, psilocybin and other psychedelics to provide the expected health benefits and unanticipated side effects, dependence on obtaining and maintaining regulatory approvals, including acquiring and renewing federal, provincial, municipal, local or other licenses and engaging in activities that could be later determined to be illegal under domestic or international laws. Ketamine and psilocybin are currently Schedule I and Schedule III controlled substances, respectively, under the Controlled Drugs and Substances Act, S.C. 1996, c. 19 (the “CDSA”) and it is a criminal offence to possess such substances under the CDSA without a prescription or a legal exemption. Health Canada has not approved psilocybin as a drug for any indication, however ketamine is a legally permissible medication for the treatment of certain psychological conditions. It is illegal to possess such substances in Canada without a prescription.
These factors should be considered carefully, and readers are cautioned not to place undue reliance on such forward-looking statements.
Although the Company has attempted to identify important risk factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other risk factors that cause actions, events or results to differ from those anticipated, estimated or intended. Additional information identifying risks and uncertainties that could affect financial results is contained in the Company’s filings with Canadian securities regulators, including the Amended and Restated Listing Statement dated April 15, 2021, which are available at www.sedar.com. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in forward-looking statements.
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
Cookie
Duration
Description
cookielawinfo-checkbox-analytics
11 months
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional
11 months
The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary
11 months
This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others
11 months
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance
11 months
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy
11 months
The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
View original content to download multimedia:
.webp)